Albert Schweitzer Hospital, Netherlands
jin M. Cheng
Implantation of a metallic drug-eluting stent (DES) is currently the gold standard in percutaneous coronary intervention (PCI). However, a DES has several limitations on the long-term, such as chronic local inflammation which may lead to in-stent restenosis, absence of physiological coronary vasomotion and vessel caging which makes future coronary artery bypass grafting (CABG) impossible. A bioresorbable scaffold (BRS) is designed to overcome these limitations. The first generation BRS was shown to be clinically inferior to DES due to a slightly higher rate of stent thrombosis. To overcome this problem, several scientific developments have been achieved in the past few years, such as thinner BRS strut construction and improved implantation technique by using intracoronary imaging guidance with optical coherence tomography (OCT) or intravasculair ultrasound (IVUS). The investigators hypothesize that combining the use of a second generation thin-strut BRS and a protocolized implantation technique with intracoronary imaging guidance leads to favourable clinical outcomes. The aim of this study is to evaluate clinical outcome after protocolized intracoronary imaging-guided PCI with implantation of a second generation thin-struts BRS.
Coronary Arterial Disease (CAD)
Percutaneous Coronary Intervention (PCI)
Percutaneous coronary intervention with protocolized implantation of a second generation thin-strut bioresorbable scaffold guided by intracoronary imaging
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 117 participants |
Official Title : | OPtimal stEnt Deployment stRategy oF Contemporary sTents - Registry to Evaluate Percutaneous Coronary Intervention Using Bioresorbable Scaffolds With Thinner-strut Construction and Guidance by intracOronary Imaging to REduce Scaffold Failure |
Actual Study Start Date : | 2025-07 |
Estimated Primary Completion Date : | 2030-06 |
Estimated Study Completion Date : | 2030-06 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
No Location Found